Study on the Pharmacokinetics and Bioequivalence of Isosorbide 5-Mononitrate and Aspirin from Compound Isosorbide Mononitrate Sustained Release Tablets in Healthy Volunteers

胡玉钦,薛洪源,侯艳宁,刘会臣
DOI: https://doi.org/10.3321/j.issn:1001-2494.2004.12.017
2004-01-01
Abstract:OBJECTIVE To study the pharmacokinetics and bioequivalence of isosorbide 5-mononitrate and aspirin from compound isosorbide mononitrate sustained released tablets in healthy volunteers.METHODS Isosorbide mononitrate sustained release tablets and aspirin enteric-coated tablets were used as the reference preparations.In a randomized crossover design,single and multiple doses of test and reference preparations were given to 20 and 18 healthy male volunteers respectively. Isosorbide-5-mononitrate and salicylic acid concentrations were measured by ESI-MSD and DAD respectively. RESULTS After a single oral administration,the pharmacokinetic parameters of isosorbide 5-mononitrate test and control preparations were as following:AUC_~0→36 h (10 025.1±1 336.9) and (9 472.0±1 139.3)μg·h·L~-1 ;t_~max (4.7±1.0) and (4.5±0.8) h;c_~max (661.9±76.5) and (658.0±83.2) μg·L~-1 , respectively. For salicylic acid, the pharmacokinetic parameters were as AUC_~0→∞ (21 864±6 239) and (18 872±5 379) μg·h·L~-1 ;t_~max (0.8±0.4) and (4.7±1.0) h;c_~max (6 050±1 133) and (3 797±872)μg·L~-1 ,respectively. The relative bioavailability of isosorbide 5-mononitratte and salicylic acid were (105.9±6.4)% and (117.5±19.3)%,respectively. After multiple oral administration of test and reference preparations,the pharmacokinetic parameters were as following:AUC_~ss (10 333.5±1 519.2) and (10 410.5±1 767.5) μg·h·L~-1 ;t_~max (4.3±1.1) and (4.3±0.8) h;c_~max (724.8±95.5) and (786.7±110.0) μg·L~-1 ;c_~min (129.4±40.0) and (121.9±36.0) μg·L~-1 ;c_~av (430.6±63.3) and (433.8±73.6) μg·L~-1 ; DF (140.1±15.9)% and (155.2±20.7)%,respectively. The relative bioavailability of isosorbide 5-mononitrate was (100.5±13.0)%. CONCLUSION Compoud isosorbide mononitrate sustained release tablets showed bioequivalence for the isosorbide 5-mononitrate component with the reference preparation, and the AUC for the aspirin component was bioequivalent with that of the reference drug,but the test drug was more rapidly absorbed.
What problem does this paper attempt to address?